Sale of a Mammalian Cell Culture Biologics API Manufacturing Facility
Baxalta Brooklyn Park
PharmaBioSource Realty provided real estate services to Baxalta on the sale of its 215,000 SF Brooklyn Park, Minnesota mammalian cell culture biologics drug substance facility to Takeda.
- Service: Real Estate
- Sector: Biotechnology
- Sub-sector: Mammalian Cell Culture Drug Substance
- Engagement Type: Sell Side
PharmaBioSource Realty provided exclusive life sciences real estate services to divest Baxalta’s mammalian cell culture drug substance facility near Minneapolis. The facility was acquired by Takeda to manufacture Entyvio® and other biologic products. The facility houses 2 x 20,000L and 2 x 1,000L bioreactors with associated downstream suites, QC laboratories, offices and GMP warehouse space.
PharmaBioSource’s services included a benchmark valuation, buyer target identification, creation of the confidential information memorandum (CIM), data room development and due diligence support. Nine competing offers were received for the facility.